Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 22, 2010

GE and Memorial Sloan-Kettering Team Up to Study Early-Stage Colon Cancer

  • A team of scientists at GE Global Research, the technology development arm of GE Healthcare, has launched a study with Memorial Sloan-Kettering Cancer Center (MSKCC) to better understand the early stages of colon cancer.

    "With colon cancer, we know that not all cases in the early stages of the disease are alike. Some are more aggressive than others," notes John Burczak, chief scientist for molecular imaging at GE Global Research. "Through the promise of molecular analysis, we can identify those patients at higher risk and help ensure they receive the best possible treatment option."

    As part of the study, GE and MSKCC will collaborate to evaluate biomarkers for their prognostic value to segregate high- from low-risk early-stage colon cancers. They will work together to first identify cancer cases, acquire and process cancer tissues, collect treatment outcome information, biochemically and statistically analyze the molecular profiles for the cancer tissues, and relate the molecular profiles to treatment outcomes.

    The research will leverage GE's molecular pathology technology that can create a visual map of more than 25 proteins within a single tissue sample at the subcellular level. It applies imaging-analysis tools to collect and interpret the data.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »